Skip to main content
. Author manuscript; available in PMC: 2014 Mar 3.
Published in final edited form as: Cancer. 2013 Feb 21;119(10):1776–1783. doi: 10.1002/cncr.27995

Table 3.

Comparison of Post-treatment Breast MRI Performance for pCR* in Patients with HER2+ Tumors Treated With and Without Trastuzumab

Trastuzumab Use** HR+/−Her2+ Sensitivity Specificity NPV PPV Accuracy
Yes 98/129 (76) 32/65 (49) 32/63 (51) 98/131 (75) 130/194 (67)
No 39/44 (89) 3/10 (30) 3/8 (38) 39/46 (85) 42/54 (78)
p value 0.07 NS NS 0.16 0.12
*

pCR: resolution of invasive disease and DCIS

**

Use of trastuzumab unknown in one HR+HER2+ patient